Genmab A/S

Common Name
Genmab
Country
Denmark
Sector
Healthcare
Industry
Biotechnology
Employees
2,639
Ticker
GMAB
Exchange
NASDAQ COPENHAGEN A/S
Description
Genmab A/S is an international biotechnology company focused on the research, development, and commercialization of innovative antibody-based therapies. Its primary mission is to transform the treatme...

Genmab's GHG Emissions Data Preview

In 2024, Genmab completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Genmab has also provided a category-level breakdown for 6 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)2024202320222021 - 2017
Total Scope 1
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
b
0000000
Total Scope 2
Market-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
b
0000000
Location-Based
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
0000000
Total Scope 3
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
c
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
a
Copy restricted. Please purchase to unlock this data.
b
0000000
Download Data

Verified Sources Behind Genmab’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Genmab’s data sources below and access millions more through our Disclosure Search.

a. Genmab's Annual Report 2024
a. Genmab's Annual Report 2024
b. Genmab's Corporate Responsibility Report (CRR) 2022
b. Genmab's Corporate Responsibility Report (CRR) 2022
c. Genmab's Annual Report 2023
c. Genmab's Annual Report 2023

Insights into Genmab's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Genmab amounted to 3,239 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2). a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Genmab increased by 113.51%, suggesting that the company faced challenges in reducing its emissions from its core operations. a

Genmab's Scope 1 Emissions Over Time

20212022202320240150300450600tCO2e-17%+12%+68%
  • Total Scope 1
  • Year-over-Year Change

What are Genmab's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Genmab were 534 metric tons of CO₂ equivalent (tCO₂e). a

Has Genmab reduced its Scope 1 emissions over time?

Since 2021, Genmab's Scope 1 emissions have increased by 56.51%, reflecting a rising long-term trend in Scope 1 emissions over time. a b

Compared to the previous year (2023), Genmab's Scope 1 emissions increased by 68.45%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations. a

What are Genmab's Scope 2 emissions?

In 2024, Genmab reported Scope 2 greenhouse gas (GHG) emissions of 1,163 tCO₂e using the market-based method and 2,705 tCO₂e using the location-based method. a

Has Genmab reduced its Scope 2 emissions over time?

Compared to the previous year (2023), Genmab's Scope 2 emissions (Location-Based) rose by 125.42% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy a

What methodology does Genmab use for Scope 2 reporting?

In 2024, Genmab reported its Scope 2 emissions using the market-based method and using the location-based method. a

Genmab's Scope 2 Emissions Over Time

202120222023202407001.4 k2.1 k2.8 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Genmab's Value Chain Emissions

In 2024, Genmab reported 187,976 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain. a

The 2024 disclosure of Genmab includes a breakdown across 6 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year. a

Genmab's Scope 3 Emissions Over Time

202220232024050 k100 k150 k200 ktCO2e+2%+25%
  • Total Scope 3
  • Year-over-Year Change

What are Genmab's Scope 3 emissions?

In 2024, Genmab reported total Scope 3 emissions of 187,976 metric tons of CO₂ equivalent (tCO₂e). a

Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment. a

Compared to the previous year (2023), Genmab's Scope 3 emissions increased by 24.56%, suggesting that the company faced challenges in reducing emissions across its value chain. a

What categories of Scope 3 emissions does Genmab disclose?

In 2024, Genmab reported emissions for 6 out of the 15 Scope 3 categories defined by the GHG Protocol. a

This partial disclosure allows for some insight into the company's indirect impacts.

What are the main sources of Genmab's Scope 3 emissions?

In 2024, the largest contributors to Genmab's Scope 3 emissions were: a

  • Purchased Goods and Services (Cat. 1): 164,449 tCO₂e (87.48%)
  • Business Travel (Cat. 6): 10,559 tCO₂e (5.62%)
  • Capital Goods (Cat. 2): 5,519 tCO₂e (2.94%)

Genmab's Scope 3 Emissions by Categories

Purchased Goods andServices (Cat. 1)(87.5%)Business Travel(Cat. 6)(5.6%)Capital Goods(Cat. 2)(2.9%)

Insights into Genmab’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Genmab reported Scope 1 greenhouse gas (GHG) emissions of 534 tCO₂e and total revenues of USD 3,003 millions. This translates into an emissions intensity of 0.18 tCO₂e per millions USD. a

Genmab's Scope 1 Emissions Intensity Compared to Peers

5501,00010,000100,000Scope 1 Emissions (tCO2e)2205005,000100,000Revenues (Millions of USD)IncyteYear: 2024Scope 1: 9,576 tCO2eRevenue: $M 4,241Scope 1 Intensity: 2.26 tCO2e/$MInsmedYear: 2024Scope 1: 1,666 tCO2eRevenue: $M 364Scope 1 Intensity: 4.58 tCO2e/$MBavarian NordicYear: 2023Scope 1: 4,364 tCO2eRevenue: $M 1,046Scope 1 Intensity: 4.17 tCO2e/$MALK-AbelloYear: 2023Scope 1: 10,256 tCO2eRevenue: $M 714Scope 1 Intensity: 14.36 tCO2e/$MInnovent BiologicsYear: 2023Scope 1: 65 tCO2eRevenue: $M 953Scope 1 Intensity: 0.07 tCO2e/$MUcbYear: 2024Scope 1: 21,718 tCO2eRevenue: $M 6,402Scope 1 Intensity: 3.39 tCO2e/$MAscendis PharmaYear: 2024Scope 1: 62 tCO2eRevenue: $M 443Scope 1 Intensity: 0.14 tCO2e/$MGubraYear: 2023Scope 1: 6 tCO2eRevenue: $M 30Scope 1 Intensity: 0.20 tCO2e/$MCelltrionYear: 2024Scope 1: 27,147 tCO2eRevenue: $M 2,424Scope 1 Intensity: 11.20 tCO2e/$MCamurusYear: 2024Scope 1: 116 tCO2eRevenue: $M 169Scope 1 Intensity: 0.68 tCO2e/$MCytokineticsYear: 2024Scope 1: 242 tCO2eRevenue: $M 18Scope 1 Intensity: 13.10 tCO2e/$MAlnylam PharmaceuticalsYear: 2024Scope 1: 3,832 tCO2eRevenue: $M 2,248Scope 1 Intensity: 1.70 tCO2e/$MBeOne MedicinesYear: 2024Scope 1: 3,547 tCO2eRevenue: $M 27,369Scope 1 Intensity: 0.13 tCO2e/$MPharmaron BeijingYear: 2024Scope 1: 34,268 tCO2eRevenue: $M 1,682Scope 1 Intensity: 20.37 tCO2e/$MJacobio Pharmaceuticals GroupYear: 2023Scope 1: 34 tCO2eRevenue: $M 10Scope 1 Intensity: 3.48 tCO2e/$MAsymchem Laboratories (Tianjin)Year: 2023Scope 1: 46,854 tCO2eRevenue: $M 1,101Scope 1 Intensity: 42.55 tCO2e/$MValnevaYear: 2024Scope 1: 1,277 tCO2eRevenue: $M 176Scope 1 Intensity: 7.24 tCO2e/$MWuXi Biologics (Cayman)Year: 2023Scope 1: 32,687 tCO2eRevenue: $M 2,603Scope 1 Intensity: 12.56 tCO2e/$MAlphamab OncologyYear: 2023Scope 1: 3,970 tCO2eRevenue: $M 34Scope 1 Intensity: 117.90 tCO2e/$MBioMarin PharmaceuticalYear: 2022Scope 1: 14,000 tCO2eRevenue: $M 2,096Scope 1 Intensity: 6.68 tCO2e/$MGenor Biopharma HoldingsYear: 2022Scope 1: 18 tCO2eRevenue: $M 3Scope 1 Intensity: 7.17 tCO2e/$MIonis PharmaceuticalsYear: 2024Scope 1: 2,616 tCO2eRevenue: $M 705Scope 1 Intensity: 3.71 tCO2e/$MZealand PharmaYear: 2024Scope 1: 145 tCO2eRevenue: $M 9Scope 1 Intensity: 16.60 tCO2e/$MGenmabYear: 2024Scope 1: 534 tCO2eRevenue: $M 3,003Scope 1 Intensity: 0.18 tCO2e/$M

How does Genmab's GHG emissions intensity compare to its peers?

In 2024, Genmab reported a Scope 1 emissions intensity of 0.18 tCO₂e per millions USD. Compared to the peer group median of 4.58 , this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors. a

Where does Genmab rank on GHG emissions intensity within its industry?

In 2024, Genmab ranked 4 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD). a

This places Genmab among the top performers, with one of the lowest emissions intensities relative to peers. a

Insights into Genmab's Total Carbon Footprint

In 2024, Genmab reported a total carbon footprint of 191,215 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 25.45% increase compared to 2023, suggesting a rise in emissions across its operations or value chain. a

The largest contributor to Genmab's total carbon footprint was Scope 3 emissions, accounting for 98.31% of the company's total carbon footprint, followed by Scope 2 emissions at 1.41%. a

Want Full Access to Genmab's GHG Emissions Dataset?
Sign Up